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Schizophrenia is a chronic disorder with a high risk of
poor outcome in terms of symptoms and social func-
tioning and possibly also progressive brain alterations.
The relapse rate is high and each relapse can induce
further aggravations. Thus, long-term treatment with
the highest degree of effectiveness should be provided to
the patients. Amongst others, the suitable drug for the
individual patient has to be selected as well as the high
risk of non-compliance to be carefully considered.
All the available evidence from randomised controlled
studies indicates that antipsychotic medications substan-
tially reduce the risk of relapse. The lowest dose should
be chosen at which preferably no side effects occur, the
risk of relapse seems to be optimally reduced and, if
symptoms are still present, suppression of these is opti-
mised. Side effects have to be assessed and, if necessary,
pharmacotherapy has to be adjusted.
Despite several methodological design issues, second-
generation antipsychotics have proven superior efficacy
in preventing relapse to FGAs. Available studies of the
specific agents supply evidence for periods of up to
2 years. Due to the decreased risk of EPS, especially
tardive dyskinesia and the superior efficacy in improving
negative, cognitive and depressive symptoms, second-
generation antipsychotics should be preferred in long-
term treatment.
Given all the known problems in compliance and dis-
continuation, which were underlined in recent years by
the CATIE and the EUFEST study, depot preparations
should be considered for optimum effectiveness in pre-
venting relapse. Altogether, randomised, control-group
studies to determine the long-term advantages of depot
preparations of atypical neuroleptics compared to depots
of typical neuroleptics are still lacking. However, the
huge database for long acting injectable risperidone is so
convincing in terms of efficacy, tolerability and effective-
ness that its special place in the long-term treatment of
schizophrenia becomes obvious.
The target strategy in long-term treatment of schizo-
phrenia should be a combination of long-term antipsy-
chotic treatment and psycho- and sociotherapeutic
procedures, so that the relapse rate is further reduced
and the course of disease can be further improved.
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